Sentiment Summary
Recent Events
Top-line results from the 48-week Phase 2 clinical trial of 'DD01', a MASH treatment, are expected to be announced by May 2026; high impact estimated as clinical data is a major catalyst expected.
Yuhan Corp is expected to announce its Q1 2026 earnings results around May 18, 2026. Analysts forecast a significant year-over-year increase in operating profit, with FnGuide consensus projecting 31 billion KRW (+384.4% YoY) and NH Investment & Securities forecasting 17.3 billion KRW (+170% YoY). Medium importance is estimated as this growth is likely to impact the price by at least 5%, scheduled.
Jiangsu Hengrui Pharmaceuticals will hold a board meeting on April 22, 2026, to consider and approve the company's quarterly results for the three months ended March 31, 2026, scheduled. A medium impact is estimated as quarterly results often lead to significant price volatility.
Q1 2026 earnings release for Apr 22, 2026; medium importance estimated due to typical earnings volatility scheduled.
The company plans to hold its annual general meeting on April 16, 2026, to review the 2025 annual profit distribution plan and elect the new board of directors, scheduled. A low impact is estimated as AGM outcomes are typically aligned with prior announcements.
The 'B' marker will be removed from the company's stock code, effective April 14, 2026, as approved by the Hong Kong Stock Exchange. This signifies the company has met the required market capitalization and revenue thresholds for a commercial-stage company. This milestone is expected to significantly improve liquidity and institutional appeal, likely resulting in a price impact of 10% or more scheduled.
Celltrion's ADC anti-cancer drug candidate 'CT-P71' to receive U.S. FDA Fast Track designation for urothelial carcinoma on April 9, 2026; this major regulatory milestone is estimated to have a high price impact (≥10%) by accelerating the drug's development and review process, expected.
A competitor, Camurus, filed an international patent for a long-acting formulation of Tirzepatide on April 9, 2026, potentially impacting Peptron's collaboration with Eli Lilly; internal analysis suggests a price impact ≥5% due to increased competitive pressure, expected and estimated.
Strategic collaboration with Mimulus Corp. on April 9, 2026, to industrialize DNA-based data storage technology; medium importance estimated based on typical market reaction to strategic partnerships and collaboration scheduled.
Received US FDA approval for the Investigational New Drug (IND) application for TQB3205, a Pan-KRAS inhibitor, announced on April 9, 2026; estimated 1-5% impact as IND is an early-stage milestone, expected.
Naldemedine was approved for marketing in the GBA area for treating opioid-induced constipation, announced on April 9, 2026; estimated 1-5% impact due to regional market scope, expected.
Innovent's CDMO business, Altruist Biologics, received a license from China's NMPA on 2026-04-09 for its large-scale production plant in Hangzhou.
Celltrion's biosimilar 'Truxima' expected to be reported as the U.S. market leader with 35.8% share on April 8, 2026; this strong market performance is estimated to have a medium price impact (≥5%) by confirming competitive dominance, expected.
ABL Bio's partner, Compass Therapeutics, received Orphan Drug Designation (ODD) from the U.S. FDA for the biliary tract cancer treatment Tovecimig (ABL001) on April 8, 2026. Medium impact estimated as ODD provides significant regulatory and commercial advantages, expected.
On April 8, 2026, the company granted 4.85 million restricted shares to 425 employees and directors under its 2024 share incentive plan.
Announced the resignation of Ms. Yuen Wing Yan as a joint company secretary and authorized representative, and the appointment of Ms. Au-Yeung Nelly as her successor, effective April 8, 2026, scheduled.
Announced on April 8, 2026, that the Hong Kong Stock Exchange granted listing approval on April 2 for the conversion of 8,214,278 domestic and unlisted foreign shares into H-shares for trading.
Announced a new technology license-in agreement with Phian-Biotechnology for a new drug mechanism. The total potential deal value is over 10% of the company's equity capital. A medium impact is estimated due to the significant deal size.
Scheduled presentation of updated Phase Ib/II data for Cadonilimab in NSCLC at ELCC 2026 on 2026-04-06; positive clinical progress in major indications typically drives >5% price impact scheduled.